Experience with ustekinumab for the treatment of moderate to severe Hidradenitis suppurativa
- 24 May 2011
- journal article
- research article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 26 (7) , 911-914
Abstract
Background Hidradenitis suppurativa (HS) is a severe chronic inflammatory follicular disease characterized by nodules and abscesses affecting apocrine gland‐bearing regions. HS is not well‐controlled with conventional medical therapies such as topical therapy, oral antibiotics and retinoids, however, abrogation of tumour necrosis factor‐α (TNF‐α) function has proven effective in some patients.Objective To assess the safety and efficacy of the interleukin‐12/23 inhibitor, ustekinumab for treatment of HS in three patients with moderate‐severe disease.Methods The subjects received 3–45 mg subcutaneous injections of ustekinumab at 0, 1 and 4 months. Improvement was assessed by the dermatology life quality index (DLQI), visual analogue scale of pain (VAS) and physician’s global assessment (PGA) at each monthly visit.Results Prior to treatment, subjects had moderate‐severe HS (Hurley stage II‐III) with a DLQI score between 8 and 12. At 6 months, one patient showed complete disease remission, while a 25–49% improvement was seen in a second patient and no change in a third. A moderate but statistically significant relationship was observed between VAS and DLQI scores (r = 0.75; P < 0.01).Conclusion Ustekinumab may provide a safe and effective new treatment strategy for HS in some patients. Interleukin 12/23 inhibition is a potential therapeutic option for patients in which other therapies prove ineffective.Keywords
This publication has 21 references indexed in Scilit:
- Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: A randomized, double-blind, placebo-controlled crossover trialJournal of the American Academy of Dermatology, 2010
- Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesityBritish Journal of Dermatology, 2009
- Hidradenitis suppurativa: A comprehensive reviewJournal of the American Academy of Dermatology, 2009
- Treatment of Hidradenitis Suppurativa with Tumour Necrosis Factor-alpha InhibitorsActa Dermato-Venereologica, 2009
- What causes hidradenitis suppurativa?Experimental Dermatology, 2008
- Is there a role for infliximab in the current therapy of hidradenitis suppurativa? A report of three treated casesInternational Journal of Dermatology, 2007
- Quality of life impairment in hidradenitis suppurativa: A study of 61 casesJournal of the American Academy of Dermatology, 2007
- Infliximab for severe hidradenitis suppurativa: Transient clinical efficacy in 7 consecutive patientsJournal of the American Academy of Dermatology, 2007
- Hidradenitis suppurativa associated with Crohn?s disease and spondyloarthropathy: response to anti-TNF therapyJournal of Gastroenterology, 2003
- Hidradenitis SuppurativaJournal of Cutaneous Medicine and Surgery, 2002